REPROCELL USA Inc. (“REPROCELL USA”) announced the opening of a new cell culture facility compliant with Good Manufacturing Practice (GMP) standards, further strengthening its regenerative medicine manufacturing capabilities.
An opening ceremony was held on April 7, 2026, at the Facility, attended by President and Global CEO Dr. Yokoyama, REPROCELL USA CEO Mr. Rama Modali, and Maryland Lieutenant Governor Aruna Miller.
REPROCELL USA has an established track record producing clinical-grade iPSCs, including its proprietary StemRNA™ Clinical iPSC Seed Clones, manufactured in compliance with FDA, EMA, and PMDA regulatory standards. These clinical cell products are widely used by biopharmaceutical companies globally.
The new facility expands manufacturing capabilities beyond seed iPSCs and master cell banks to include regenerative medicine products, enhancing support across preclinical development through commercial-scale production.
Looking ahead, REPROCELL will continue scaling its CDMO business to meet growing demand for high-quality, regulatory-compliant cell therapy manufacturing while focusing on innovation and long-term sustainable growth.
From left: Dr. Yokoyama (President and Global CEO), Mr. Modali (REPROCELL USA CEO), and Ms. Aruna Miller (Lieutenant Governor of Maryland)